Table of Content

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Market Definition and Overview
3. Executive Summary
4. Market Dynamics
4.1. Market Impacting Factors
4.1.1. Drivers:
4.1.1.1. Rising prevalence concerning Lyme disease
4.1.1.2. Growing Technological Advancement
4.1.2. Restraints:
4.1.2.1. Adverse effects associated with bronchodilators
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1 Porter’s Five Forces Analysis
5.2 Regulatory Analysis
5.3 Supply Chain Analysis
5.4 Pricing Analysis
6. By Drug Type
6.1. Introduction
6.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
6.1.2. Market Attractiveness Index, By Drug Type
6.2. Sympathomimetics
6.2.1. Introduction
6.2.2. Market Size Analysis, US$ Mn and Y-o-Y Growth Analysis (%), 2021-2029
6.3. Anticholinergics
6.4. Phosphodiesterase Inhibitor
6.5. Combination Drugs
6.6. Others
7. By Mode of Action
7.1. Introduction
7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Mode of Action
7.1.2. Market Attractiveness Index, By Mode of Action
7.2. Long-Acting Bronchodilators
7.2.1. Introduction
7.2.2. Market Size Analysis, US$ Mn and Y-o-Y Growth Analysis (%), 2021-2029
7.3. Short-Acting Bronchodilators
8. By Indication
8.1. Introduction
8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
8.1.2. Market Attractiveness Index, By Indication
8.2. Asthma
8.2.1. Introduction
8.2.2. Market Size Analysis, US$ Mn and Y-o-Y Growth Analysis (%), 2021-2029
8.3. Chronic obstructive pulmonary disease (COPD)
8.4. Others
9. By Route of Administration
9.1. Introduction
9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
9.1.2. Market Attractiveness Index, By Route of Administration
9.2. Oral
9.2.1. Introduction
9.2.2. Market Size Analysis, USD Mn and Y-o-Y Growth Analysis (%), 2021-2029
9.3. Injection
9.4. Inhalers
10. By Region
10.1. Introduction
10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
10.1.2. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Mode of Action
10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
10.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
10.2.7.1. The U.S.
10.2.7.2. Canada
10.2.7.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Mode of Action
10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
10.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
10.3.7.1. Germany
10.3.7.2. The U.K.
10.3.7.3. France
10.3.7.4. Rest of Europe
10.4. South America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Mode of Action
10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
10.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
10.4.7.1. Brazil
10.4.7.2. Argentina
10.4.7.3. Rest of South America
10.5. Asia Pacific
10.5.1. Introduction
10.5.2. Key Region-Specific Dynamics
10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Mode of Action
10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
10.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
10.5.7.1. China
10.5.7.2. India
10.5.7.3. Japan
10.5.7.4. Australia
10.5.7.5. Rest of Asia Pacific
10.6. The Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Mode of Action
10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
10.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
11. Competitive Landscape
11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis
12. Company Profiles
12.1. Abbott Laboratories
12.1.1. Company Overview
12.1.2. Form Portfolio and Description
12.1.3. Key Highlights
12.1.4. Financial Overview
12.2. AstraZeneca plc.
12.3. Boehringer Ingelheim International GmbH
12.4. GlaxoSmithKline Plc.
12.5. F. Hoffmann-La Roche Ltd.
12.6. Novartis AG.
12.7. Pfizer Inc.
12.8. Sanofi
12.9. Teva Pharmaceutical Industries Ltd.
12.10. Vectura Group Plc.
LIST NOT EXHAUSTIVE
13. Global Bronchodilators Market – DataM
13.1. Appendix
13.2. About Us and End User
13.3. Contact Us